Cassava Sciences, Inc. (SAVA) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Cassava Sciences, Inc. (SAVA) Stock Price, Quote & News - Stock Analysis? ›

Cassava Sciences has a consensus rating of Moderate Buy which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings. The average price target for Cassava Sciences is $107.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

Cassava Sciences has a consensus rating of Moderate Buy which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings. The average price target for Cassava Sciences is $107.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

$105.06 ↑260.91% Estimated share price by June 12, 2025.

Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of SAVA, demonstrate its potential to perform inline with the market. It currently has a Growth Score of F.

SAVA Signals & Forecast

Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $28.03.

This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH). Indeed, Hoau-Yan Wang, a professor at the City University of New York (CUNY), was charged with fraud of over $16 million in grants.

Kirklands stock prediction for 1 year from now: $ 2.18 (49.73%) Kirklands stock forecast for 2025: $ 2.80 (93.44%) Kirklands stock prediction for 2030: $ 75.98 (5,139.78%)

Why is SAVA tanking? ›

NASDAQ: SAVA

The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava. Wang was accused of fraud related to grant applications made to the U.S. National Institutes of Health (NIH) for work on Cassava's experimental drug simufilam.

The ownership structure of Cassava Sciences (SAVA) stock is a mix of institutional, retail and individual investors. Approximately 18.11% of the company's stock is owned by Institutional Investors, 34.10% is owned by Insiders and 47.80% is owned by Public Companies and Individual Investors.

The average one-year price target for Vulcan Energy Resources Limited is $10.48. The forecasts range from a low of $3.74 to a high of $17.97. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

The current TTM dividend payout for Cassava Sciences (SAVA) as of August 06, 2024 is $0.00. The current dividend yield for Cassava Sciences as of August 06, 2024 is 0.00%.